Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients had at least one International Classification of Diseases, 10th Revision (ICD-10) diagnosis code for DLBCL.
Patients received CAR-T therapy, including both tisa-cel and axi-cel, following DLBCL diagnosis. The administration date of CAR-T therapy was defined as the index date.
Patients were at least 18 years of age as of the index date.
Patients had at least three months of continuous health plan enrollment before the index date.
You may not be if
Patients who had a medical claim associated with a clinical trial within one month before and after the index date.
Patients who had zero cost on index date for CAR-T infusion.
Clareo Health | Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.
